ArticleFrontiers in oncology2026
Retroperitoneal paraganglioma mimicking a solid pseudopapillary neoplasm of the pancreatic tail and confirmed by percutaneous biopsy: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retroperitoneal paraganglioma (RPGL) is an uncommon extra-adrenal neuroendocrine tumor. When located adjacent to the pancreas, RPGL may mimic solid pseudopapillary neoplasm of the pancreas (SPN/SPTP) because both lesions may present as large cystic-solid masses with nonspecific symptoms and non-diagnostic conventional tumor markers. Percutaneous biopsy may establish the diagnosis but can be hazardous when RPGL has not been excluded. Case presentation: A 44-year-old man presented with abdominal distension. He had no history of hypertension, headache, palpitations, or profuse sweating. Laboratory tests, including routine blood tests, liver and kidney function, coagulation profile, and conventional tumor markers, showed no significant abnormalities. Ultrasound, CT, and MRI demonstrated a large multilocular cystic-solid mass in the pancreatic body-tail region, and the initial impression was SPN/SPTP or a pancreatic cystic neoplasm. Plasma or urinary catecholamines/metanephrines and functional imaging were not performed because the lesion was initially considered pancreatic in origin and the patient lacked symptoms of catecholamine excess. Ultrasound-guided 16G core biopsy yielded two tissue cores. Histology and immunohistochemistry showed synaptophysin, chromogranin A, and CD56 positivity with a Ki-67 index of approximately 1%, supporting RPGL. Surgical exploration subsequently confirmed that the tumor arose from the retroperitoneum and compressed, rather than originated from, the pancreas. Tumor manipulation caused marked hemodynamic fluctuation and pulmonary edema, requiring postoperative intensive care. Final pathology confirmed RPGL without definite evidence of metastasis or local malignant invasion. Conclusion: For large cystic-solid masses in the pancreatic tail or adjacent retroperitoneum, RPGL should remain in the differential diagnosis even when classic catecholamine-related symptoms are absent. Before biopsy, clinicians should prioritize careful assessment of tumor origin, multiphasic contrast-enhanced imaging, and biochemical testing for plasma free or urinary fractionated metanephrines. Biopsy should be selective and should follow multidisciplinary risk assessment with appropriate hemodynamic and interventional contingency planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.